- A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Gray, J.E., Haura, E., Chiappori, A., Tanvetyanon, T., Williams, C.C., Pinder-Schenck, M., Kish, J.A., Kreahling, J., Lush, R., Neuger, A., Tetteh, L., Akar, A., Zhao, X., Schell, M.J., Bepler, G., Altiok, S. Clin. Cancer Res. (2014)